drugset / Trial / NCT00930982

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

NCT00930982

Phase 2 Completed 124 enrolled Bayer Novartis · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.

Timeline

Start
2009-06
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 32.5 mg Inhaled

Indications